Drug Profile
STRO 001
Alternative Names: BN-301; STRO-001Latest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator Sutro Biopharma
- Developer BioNova Pharmaceuticals; Sutro Biopharma
- Class Antibodies; Antineoplastics; Drug conjugates; Immunotoxins; Maytansinoids
- Mechanism of Action Apoprotein stimulants; Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-Hodgkin's lymphoma
- Phase I Acute myeloid leukaemia; Haematological malignancies; Multiple myeloma
- Preclinical Leukaemia
- No development reported Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
Most Recent Events
- 25 Dec 2023 BioNova Pharmaceuticals terminates phase I/II clinical trials in Non-Hodgkin's lymphoma (Late-stage disease, Second-line therapy or greater) in China (IV) due to company decision (NCT05611853)
- 28 May 2023 No recent reports of development identified for phase-I development in Multiple-myeloma(Late-stage disease, Second-line therapy or greater) in USA (IV)
- 28 May 2023 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Late-stage disease, Second-line therapy or greater) in USA (IV)